Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy

INTRODUCTION: With the current consensus approach, the definition of non-alcoholic fatty liver disease has been changed to 'fatty liver disease associated with metabolic dysfunction' (MAFLD). This study aimed to investigate the company of MAFLD in isolated AntiHBC Ig G positive hepatitis B...

Full description

Bibliographic Details
Main Authors: Çiğdem Mermutluoğlu, Mustafa Celen
Format: Article
Language:English
Published: Van Yuzuncu Yil University, School of Medicine 2023-10-01
Series:Van Tıp Dergisi
Subjects:
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-94580
_version_ 1797412664970838016
author Çiğdem Mermutluoğlu
Mustafa Celen
author_facet Çiğdem Mermutluoğlu
Mustafa Celen
author_sort Çiğdem Mermutluoğlu
collection DOAJ
description INTRODUCTION: With the current consensus approach, the definition of non-alcoholic fatty liver disease has been changed to 'fatty liver disease associated with metabolic dysfunction' (MAFLD). This study aimed to investigate the company of MAFLD in isolated AntiHBC Ig G positive hepatitis B patients who need immunosuppressive therapy for various reasons. METHODS: The presence of MAFLD was prospectively investigated before starting treatment in 150 patients with isolated AntiHBC IgG positivity who needed immunosuppressive therapy for a reason such as a rheumatological disease or tumor. All patients were scanned with Fibroscan M530 before immunosuppressive therapy and CAP value was determined. Simultaneously, blood lipid level, HOMA score, fasting insulin and fasting blood glucose were measured. RESULTS: Oral antiviral therapy was started in all patients who needed immunosuppressive therapy and had isolated AntiHBc IgG positivity. CAP was measured with fibroscan M530 in all patients included in this study.This situation is accepted as F: 0-1 according to metavir. The patients' average CAP value was 235.2 dB/m with the exact measurement. In this case, although the mean value was <248 dB/m, MAFLD was detected in 28.1% of the cases. DISCUSSION AND CONCLUSION: In this study, MAFLD was found in 28.1% of patients with low liver fibrosis but isolated AntiHBc IgG positivity requiring immunosuppressive treatment and to be started oral antiviral to prevent HBV reactivation.
first_indexed 2024-03-09T05:06:23Z
format Article
id doaj.art-d345535a3da343b4836373c999d40b7c
institution Directory Open Access Journal
issn 2587-0351
language English
last_indexed 2024-03-09T05:06:23Z
publishDate 2023-10-01
publisher Van Yuzuncu Yil University, School of Medicine
record_format Article
series Van Tıp Dergisi
spelling doaj.art-d345535a3da343b4836373c999d40b7c2023-12-03T12:54:57ZengVan Yuzuncu Yil University, School of MedicineVan Tıp Dergisi2587-03512023-10-0130439640010.5505/vtd.2023.94580VTD-94580Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive TherapyÇiğdem Mermutluoğlu0Mustafa Celen1Department Of Infectious Diseases And Clinical Microbiology,dicle University Faculty Of Medicine, Diyarbakır,türkiyeDepartment Of Infectious Diseases And Clinical Microbiology,dicle University Faculty Of Medicine, Diyarbakır,türkiyeINTRODUCTION: With the current consensus approach, the definition of non-alcoholic fatty liver disease has been changed to 'fatty liver disease associated with metabolic dysfunction' (MAFLD). This study aimed to investigate the company of MAFLD in isolated AntiHBC Ig G positive hepatitis B patients who need immunosuppressive therapy for various reasons. METHODS: The presence of MAFLD was prospectively investigated before starting treatment in 150 patients with isolated AntiHBC IgG positivity who needed immunosuppressive therapy for a reason such as a rheumatological disease or tumor. All patients were scanned with Fibroscan M530 before immunosuppressive therapy and CAP value was determined. Simultaneously, blood lipid level, HOMA score, fasting insulin and fasting blood glucose were measured. RESULTS: Oral antiviral therapy was started in all patients who needed immunosuppressive therapy and had isolated AntiHBc IgG positivity. CAP was measured with fibroscan M530 in all patients included in this study.This situation is accepted as F: 0-1 according to metavir. The patients' average CAP value was 235.2 dB/m with the exact measurement. In this case, although the mean value was <248 dB/m, MAFLD was detected in 28.1% of the cases. DISCUSSION AND CONCLUSION: In this study, MAFLD was found in 28.1% of patients with low liver fibrosis but isolated AntiHBc IgG positivity requiring immunosuppressive treatment and to be started oral antiviral to prevent HBV reactivation.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-94580nafldhepatitis bmetabolic syndrome
spellingShingle Çiğdem Mermutluoğlu
Mustafa Celen
Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
Van Tıp Dergisi
nafld
hepatitis b
metabolic syndrome
title Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
title_full Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
title_fullStr Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
title_full_unstemmed Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
title_short Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy
title_sort detection of mafld in patients with isolated antihbc ig g positive hepatitis b who need immunosuppressive therapy
topic nafld
hepatitis b
metabolic syndrome
url https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-94580
work_keys_str_mv AT cigdemmermutluoglu detectionofmafldinpatientswithisolatedantihbciggpositivehepatitisbwhoneedimmunosuppressivetherapy
AT mustafacelen detectionofmafldinpatientswithisolatedantihbciggpositivehepatitisbwhoneedimmunosuppressivetherapy